Track NRx Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NRx Pharmaceuticals, Inc. NRXP · Stock Open NRx Pharmaceuticals, Inc. in new tab

3.40 USD
Add to portfolio
EPS
-0.51
P/B
-867.50
Beta
2.19
Target Price
38.25 USD
NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

🧾 Earnings Recap – Q2 2026

NRx Pharmaceuticals shares rose 5.2% following Q2 results, driven by significant progress toward regulatory approvals and a promising federally backed clinical trial partnership that expands the potential market for NRX-101.

  • Completed first FDA review cycle for preservative-free ketamine ANDA with only one minor manufacturing-related deficiency remaining, targeting approval in 2026.
  • Advanced NRX-100 NDA with strong external alignment, supported by White House and Congressional guidance endorsing real-world evidence for psychedelic depression treatments; aiming for 2027 approval.
  • Secured a prime contractor role with DARPA for the SPARC-TMS trial of NRX-101 combined with robotic TMS, potentially opening a large new market in military and first responder mental health.
  • Expanded HOPE Therapeutics clinical footprint in Florida, supporting growth ambitions.
  • Ordered 5 million units of launch stock for preservative-free ketamine, reflecting confidence in upcoming commercial readiness.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 13, 2026
EPS-0.51
Book Value0.00
Price to Book-867.50
% Insiders6.343%
Estimates
Forward P/E6.94
Forward EPS0.50
Target Mean Price38.25

DCF Valuation

Tweak assumptions to recompute fair value for NRx Pharmaceuticals, Inc. (NRXP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NRx Pharmaceuticals, Inc. Logo NRx Pharmaceuticals, Inc. Analysis (NRXP)

United States Health Care Official Website Stock

Is NRx Pharmaceuticals, Inc. a good investment? NRx Pharmaceuticals, Inc. (NRXP) is currently trading at 3.40 USD. Market analysts have a consensus price target of 38.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: NRx Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is 0.50.

Investor FAQ

Does NRx Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NRx Pharmaceuticals, Inc.?

NRx Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -0.51.

Company Profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Exchange Ticker
NMS (United States) NRXP
FRA (Germany) B1Q.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 2, 2024 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion